PREVENT ALL ALS Study Launches to Collect Data on Genetic Risk for ALS
The PREVENT ALL ALS study aims to gather extensive clinical data and samples from asymptomatic individuals at genetic risk for ALS over a 36-month period.
Asset / Drug
Drug and asset intelligence for PREVENT with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.